KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

NovoCure (NVCR) Operating Expenses (2016 - 2025)

NovoCure's Operating Expenses history spans 12 years, with the latest figure at $172.6 million for Q4 2025.

  • For Q4 2025, Operating Expenses fell 9.69% year-over-year to $172.6 million; the TTM value through Dec 2025 reached $642.3 million, up 0.59%, while the annual FY2025 figure was $642.3 million, 0.59% up from the prior year.
  • Operating Expenses for Q4 2025 was $172.6 million at NovoCure, up from $158.5 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $191.1 million in Q4 2024 and bottomed at $108.4 million in Q1 2021.
  • The 5-year median for Operating Expenses is $150.5 million (2024), against an average of $143.6 million.
  • The largest annual shift saw Operating Expenses skyrocketed 39.9% in 2021 before it fell 9.69% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $126.9 million in 2021, then increased by 12.29% to $142.5 million in 2022, then increased by 7.31% to $152.9 million in 2023, then increased by 24.95% to $191.1 million in 2024, then dropped by 9.69% to $172.6 million in 2025.
  • Per Business Quant, the three most recent readings for NVCR's Operating Expenses are $172.6 million (Q4 2025), $158.5 million (Q3 2025), and $156.9 million (Q2 2025).